Cargando…
Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
PURPOSE: To describe different ocular paraneoplastic syndromes in patients treated with Immune Checkpoint Inhibitors (ICI), its relation with different types of ICI and different types of tumors, and its implications for treatment. METHODS: A comprehensive review of the literature was performed. RES...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079794/ https://www.ncbi.nlm.nih.gov/pubmed/37022562 http://dx.doi.org/10.1186/s12348-023-00338-1 |
_version_ | 1785020784092119040 |
---|---|
author | Casselman, Pauline Jacob, Julie Schauwvlieghe, Pieter-Paul |
author_facet | Casselman, Pauline Jacob, Julie Schauwvlieghe, Pieter-Paul |
author_sort | Casselman, Pauline |
collection | PubMed |
description | PURPOSE: To describe different ocular paraneoplastic syndromes in patients treated with Immune Checkpoint Inhibitors (ICI), its relation with different types of ICI and different types of tumors, and its implications for treatment. METHODS: A comprehensive review of the literature was performed. RESULTS: Patients treated with ICI can present with different ocular paraneoplastic syndromes, such as Carcinoma Associated Retinopathy (CAR), Melanoma Associated Retinopathy (MAR) and paraneoplastic Acute Exudative Polymorphous Vitelliform Maculopathy (pAEPVM). In literature, the different types of paraneoplastic retinopathy are mostly related to different types of primary tumors, with MAR and pAEPVM seen in melanoma, and CAR in carcinoma. Visual prognosis is limited in MAR and CAR. CONCLUSION: Paraneoplastic disorders result from an antitumor immune response against a shared autoantigen between the tumor and ocular tissue. ICI enhance the antitumor immune response, which can lead to increased cross-reaction against ocular structures and unmasking of a predisposed paraneoplastic syndrome. Different types of primary tumors are related to different cross-reactive antibodies. Therefore, the different types of paraneoplastic syndromes are related to different types of primary tumors and are probably unrelated to the type of ICI. ICI-related paraneoplastic syndromes often lead to an ethical dilemma. Continuation of ICI treatment can lead to irreversible visual loss in MAR and CAR. In these cases overall survival must be weighed against quality of life. In pAEPVM however, the vitelliform lesions can disappear with tumor control, which may involve continuation of ICI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12348-023-00338-1. |
format | Online Article Text |
id | pubmed-10079794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-100797942023-04-08 Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature Casselman, Pauline Jacob, Julie Schauwvlieghe, Pieter-Paul J Ophthalmic Inflamm Infect Review PURPOSE: To describe different ocular paraneoplastic syndromes in patients treated with Immune Checkpoint Inhibitors (ICI), its relation with different types of ICI and different types of tumors, and its implications for treatment. METHODS: A comprehensive review of the literature was performed. RESULTS: Patients treated with ICI can present with different ocular paraneoplastic syndromes, such as Carcinoma Associated Retinopathy (CAR), Melanoma Associated Retinopathy (MAR) and paraneoplastic Acute Exudative Polymorphous Vitelliform Maculopathy (pAEPVM). In literature, the different types of paraneoplastic retinopathy are mostly related to different types of primary tumors, with MAR and pAEPVM seen in melanoma, and CAR in carcinoma. Visual prognosis is limited in MAR and CAR. CONCLUSION: Paraneoplastic disorders result from an antitumor immune response against a shared autoantigen between the tumor and ocular tissue. ICI enhance the antitumor immune response, which can lead to increased cross-reaction against ocular structures and unmasking of a predisposed paraneoplastic syndrome. Different types of primary tumors are related to different cross-reactive antibodies. Therefore, the different types of paraneoplastic syndromes are related to different types of primary tumors and are probably unrelated to the type of ICI. ICI-related paraneoplastic syndromes often lead to an ethical dilemma. Continuation of ICI treatment can lead to irreversible visual loss in MAR and CAR. In these cases overall survival must be weighed against quality of life. In pAEPVM however, the vitelliform lesions can disappear with tumor control, which may involve continuation of ICI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12348-023-00338-1. Springer Berlin Heidelberg 2023-04-06 /pmc/articles/PMC10079794/ /pubmed/37022562 http://dx.doi.org/10.1186/s12348-023-00338-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Casselman, Pauline Jacob, Julie Schauwvlieghe, Pieter-Paul Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature |
title | Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature |
title_full | Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature |
title_fullStr | Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature |
title_full_unstemmed | Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature |
title_short | Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature |
title_sort | relation between ocular paraneoplastic syndromes and immune checkpoint inhibitors (ici): review of literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079794/ https://www.ncbi.nlm.nih.gov/pubmed/37022562 http://dx.doi.org/10.1186/s12348-023-00338-1 |
work_keys_str_mv | AT casselmanpauline relationbetweenocularparaneoplasticsyndromesandimmunecheckpointinhibitorsicireviewofliterature AT jacobjulie relationbetweenocularparaneoplasticsyndromesandimmunecheckpointinhibitorsicireviewofliterature AT schauwvlieghepieterpaul relationbetweenocularparaneoplasticsyndromesandimmunecheckpointinhibitorsicireviewofliterature |